Saturday, June 3, 2023
Home Tags PP Amarin

PP Amarin Related News

NICE recommends VAZKEPA® (icosapent ethyl) to reduce cardiovascular risk

NICE recommends VAZKEPA® (icosapent ethyl) to reduce cardiovascular risk

Icosapent ethyl has been recommended by NICE for use across the NHS in England and Wales to reduce cardiovascular (CV) risk in adult statin-treated...
cardiovascular disease prevention

Tackling cardiovascular disease in Europe

Laurent Abuaf, SVP and President Europe at Amarin, outlines the social and economic burden of CVD in Europe and the company’s key priorities for...
Amarin: Changing the landscape of residual cardiovascular disease risk

Amarin: Changing the landscape of residual cardiovascular disease risk

World-leading pioneers of the pharmaceutical industry, Amarin Corporation, comprehensively explore the ever-evolving landscape of cardiovascular disease, analysing the current challenges facing mitigating the impacts...

Health Special Reports

Health eBooks

Health Partners

Pin It on Pinterest